Mission Statement

The Applied Genetic Toxicology (AGT) Special Interest Group (SIG) aims to gather scientists form a wide variety of backgrounds including pharmaceutics, consumer products, chemical products, food sciences and environmental researchers to discuss emerging science and regulatory issues that are highly relevant to applied genetic toxicology. This includes validation of new methods for hazard identification, data driven evolution of testing paradigms, and novel tools to support risk assessment and/or management practices. SIG members and leadership will drive the annual agenda, focusing on key topics and issues that genetic toxicologists are currently facing. Partnering with other SIGs such as the Risk Assessment SIG we plan to help support EMGS strategic planning. We aim to accomplish our goals by connecting through a variety of collaborative meetings on SIG relevant topics. 

Relevant activities of this SIG may include, but are not limited to, planning and sponsoring symposia, platform sessions, breakfast meetings, social events, and workshops for the EMGS Annual Meeting, selecting awardees from among our membership, and updating members about the latest in applied genetox through our website and email forum. Overall, this SIG provides a platform for members from all sectors (academia, industry, and government agencies) to discuss and learn about the latest in genotoxicity testing applications. 

SIG Contact

If you would like more information, you can reach out to us here: AGT Contact Form

If you are already an EMGS member and are interested in joining the Applied Genetic Toxicology SIG:

Join the SIG

Search for the name of the group using the Find A Group search bar and click + Join Group.

Top Global Issues

• New tools for assessment of genotoxicity that will limit the need for in vivo testing and eventually replace it 
  •  ecNGS, 3D tissue models/tissue on a chip, H3P/gH2AX assays, gene expression assays, RADD, toxicogenomics, etc 
  • High throughput/high content multiplexed data generation and analysis strategies (including AI application) 
  • In vitro/in vivo extrapolation 
• Quantitative analysis of in vitro and in vivo genotoxicity data and dose-response modeling to challenge linear low dose extrapolation of cancer risk for mutagenic chemicals 
  • Prediction of carcinogenic risk/potency from in vivo and in vitro genotoxicity data (e.g. nitrosamine risk assessment) 
• Genotoxicity assessment of new therapeutic modalities such as gene and cell therapies 
• Evolution of regulatory genetic toxicology 
  • Modification of existing assays (e.g. standardizing the use of historical controls, EAT, addition of NAMs to help interpret results) 
  • Validation and acceptance of new assays

SIG Membership

Any EMGS member may join the SIG, serve in a leadership role (SIG Chair/Co-Chair, SIG Representative to Program Committee, Student and Early Career Investigator Co-Chair (SECI), and have voting privileges. Any EMGS Annual Meeting attendees who are not EMGS members and/or SIG members are welcome to attend the SIG meeting at the Annual Meeting. EMGS members may join or leave the SIG at any time, are encouraged to check on their membership status on the EMGS website, and can ask SIG leadership to update their membership status as necessary. EMGS members may belong to as many SIGs as they choose, and SIG memberships are free of charge. 

SIG Leadership

Leadership roles in this SIG include a Chair, Co-Chair (optional), Student and Early Career Investigator (SECI) Co-Chair, and a Representative to the Program Committee. Starting in February 2020, the responsibilities for these roles and the timelines and procedures for nominations and elections has been standardized across all EMGS SIGs. 

SIG Files

AGT SOP | EMGS Strategic Plan | 2024 Top Global Issues